Oncolix Inc. (fka ONCX)

[Rat Fink]

12/6/17 PR, "ONCX" HAS SUBMITTED APPLICATION_FOR_OTC-QB_LISTING!!!_https://finance.yahoo.com/news/oncolix-inc-announces-submission-application-123000986.html

EXCERPT FROM PR AS FOLLOWS:

HOUSTON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Oncolix, Inc., (OTC PINK:ONCX) announced today that following the appointment of the second independent member of the Board of Directors the Company has fulfilled the requirements and has submitted an application to be listed on the OTC-QB. The review is anticipated to take approximately two to four weeks after which Oncolix would be listed on the OTC-QB.

“We continue to make progress building out our public biopharmaceutical company infrastructure and today, we are finally able to realize an important step by submitting the application for listing on the OTC-QB,” said Michael T. Redman, chief executive officer of Oncolix. “We continue to meet our announced milestones, most recently changing the company name and stock ticker, appointing two independent members to our board of directors, and finishing an extensive review process by the Financial Industry Regulatory Authority (FINRA). All of these actions are directed toward our ultimate objective of a NASDAQ listing.”

About Oncolix

Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial is currently in progress. Prolanta™ is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently $2 million), federal tax credits and marketing exclusivity.